These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24954865)

  • 1. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.
    Aihara A; Huang CK; Olsen MJ; Lin Q; Chung W; Tang Q; Dong X; Wands JR
    Hepatology; 2014 Oct; 60(4):1302-13. PubMed ID: 24954865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma.
    Iwagami Y; Huang CK; Olsen MJ; Thomas JM; Jang G; Kim M; Lin Q; Carlson RI; Wagner CE; Dong X; Wands JR
    Hepatology; 2016 Apr; 63(4):1213-26. PubMed ID: 26683595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis.
    Lin Q; Chen X; Meng F; Ogawa K; Li M; Song R; Zhang S; Zhang Z; Kong X; Xu Q; He F; Bai X; Sun B; Hung MC; Liu L; Wands J; Dong X
    Mol Cancer; 2019 Nov; 18(1):156. PubMed ID: 31694640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.
    Huang CK; Iwagami Y; Aihara A; Chung W; de la Monte S; Thomas JM; Olsen M; Carlson R; Yu T; Dong X; Wands J
    PLoS One; 2016; 11(3):e0150336. PubMed ID: 26954680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
    Nagaoka K; Ogawa K; Ji C; Cao KY; Bai X; Mulla J; Cheng Z; Wands JR; Huang CK
    Dig Dis Sci; 2021 Apr; 66(4):1080-1089. PubMed ID: 32445050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxylase Activity of ASPH Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-to-Mesenchymal Transition Pathway.
    Zou Q; Hou Y; Wang H; Wang K; Xing X; Xia Y; Wan X; Li J; Jiao B; Liu J; Huang A; Wu D; Xiang H; Pawlik TM; Wang H; Lau WY; Wang Y; Shen F
    EBioMedicine; 2018 May; 31():287-298. PubMed ID: 29764768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspartate β-hydroxylase targeting in castration-resistant prostate cancer modulates the NOTCH/HIF1α/GSK3β crosstalk.
    Barboro P; Benelli R; Tosetti F; Costa D; Capaia M; Astigiano S; Venè R; Poggi A; Ferrari N
    Carcinogenesis; 2020 Sep; 41(9):1246-1252. PubMed ID: 32525968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
    Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
    Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.
    Shimoda M; Tomimaru Y; Charpentier KP; Safran H; Carlson RI; Wands J
    J Hepatol; 2012 May; 56(5):1129-1135. PubMed ID: 22245894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.
    Zhang S; Yang Y; Liang Z; Duan W; Yang J; Yan J; Wang N; Feng W; Ding M; Nie Y; Jin Z
    PLoS One; 2013; 8(12):e83699. PubMed ID: 24386256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review).
    Zheng W; Wang X; Hu J; Bai B; Zhu H
    Oncol Rep; 2020 Dec; 44(6):2364-2372. PubMed ID: 33125119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INPP5F translocates into cytoplasm and interacts with ASPH to promote tumor growth in hepatocellular carcinoma.
    Zhou Q; Lin J; Yan Y; Meng S; Liao H; Chen R; He G; Zhu Y; He C; Mao K; Wang J; Zhang J; Zhou Z; Xiao Z
    J Exp Clin Cancer Res; 2022 Jan; 41(1):13. PubMed ID: 34996491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartate β-Hydroxylase expression promotes a malignant pancreatic cellular phenotype.
    Dong X; Lin Q; Aihara A; Li Y; Huang CK; Chung W; Tang Q; Chen X; Carlson R; Nadolny C; Gabriel G; Olsen M; Wands JR
    Oncotarget; 2015 Jan; 6(2):1231-48. PubMed ID: 25483102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.
    de la Monte SM; Tamaki S; Cantarini MC; Ince N; Wiedmann M; Carter JJ; Lahousse SA; Califano S; Maeda T; Ueno T; D'Errico A; Trevisani F; Wands JR
    J Hepatol; 2006 May; 44(5):971-83. PubMed ID: 16564107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
    Xiong J; Wu JS; Mao SS; Yu XN; Huang XX
    Oncol Rep; 2016 Sep; 36(3):1483-90. PubMed ID: 27460949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIP6 promotes tumorigenic capability through regulating FOXC1 in hepatocellular carcinoma.
    Wang F; Zhang B; Xu X; Zhu L; Zhu X
    Pathol Res Pract; 2020 Apr; 216(4):152850. PubMed ID: 32046874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
    Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
    Xu QG; Yu J; Guo XG; Hou GJ; Yuan SX; Yang Y; Yang Y; Liu H; Pan ZY; Yang F; Gu FM; Zhou WP
    Mol Oncol; 2018 Jun; 12(6):936-952. PubMed ID: 29689643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.
    Gu F; Yuan S; Liu L; Zhu P; Yang Y; Pan Z; Zhou W
    J Cell Mol Med; 2019 Jun; 23(6):4208-4216. PubMed ID: 30957411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.